ArticleInvestigative ophthalmology & visual science2016
The Effect of Limiting the Range of Perimetric Sensitivities on Pointwise Assessment of Visual Field Progression in Glaucoma.
Article in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- A Bayesian Hierarchical Longitudinal Model for Estimation of Central Visual Field Rates of Change in Glaucoma.Translational vision science & technology · 2025Article
- High-Resolution Microperimetry for Detecting Glaucomatous Damage: A Prospective Evaluation of Performance.Clinical & experimental ophthalmology · 2025Article
- Personalizing the Transition From 24-2 to 10-2 Visual Field Testing Using ARREST - A Simulation Study.Translational vision science & technology · 2025Article
- Comparison of the Humphrey Field Analyzer and MP-3 Microperimeter in Patients With Glaucoma, Classified by Severity and Misalignment of Test Points.Translational vision science & technology · 2025Article
- Relating Standardized Automated Perimetry Performed With Stimulus Sizes III and V in Eyes With Field Loss Due to Glaucoma and NAION.Translational vision science & technology · 2024Article
- Spatial Summation in the Glaucomatous Macula: A Link With Retinal Ganglion Cell Damage.Investigative ophthalmology & visual science · 2023Article
- Validation of the Iowa Head-Mounted Open-Source Perimeter.Translational vision science & technology · 2023Article
- Suprathreshold Approaches to Mapping the Visual Field in Advanced Glaucoma.Translational vision science & technology · 2023Article
- Longitudinal Signal-to-Noise Ratio of Perimetry at Different Severities of Glaucoma.Translational vision science & technology · 2023Article
- Impact of Smoking on Visual Field Progression in a Long-term Clinical Follow-up.Ophthalmology · 2022Article
- Moving Stimulus Perimetry: A New Functional Test for Glaucoma.Translational vision science & technology · 2022Article
- The Usefulness of Assessing Glaucoma Progression With Postprocessed Visual Field Data.Translational vision science & technology · 2022Article
- Benefit of Stimulus Size V Perimetry for Patients With a Dense Central Scotoma From Leber's Hereditary Optic Neuropathy.Translational vision science & technology · 2021Article
- Hierarchical Censored Bayesian Analysis of Visual Field Progression.Translational vision science & technology · 2021Article
- Non-invasive electrophysiology in glaucoma, structure and function-a review.Eye (London, England) · 2021Review
- Development and validation of a visual field cluster in retinitis pigmentosa.Scientific reports · 2021Article
- Slowed Saccadic Reaction Times in Seemingly Normal Parts of Glaucomatous Visual Fields.Frontiers in medicine · 2021Article
- Increasing the Spatial Resolution of Visual Field Tests Without Increasing Test Duration: An Evaluation of ARREST.Translational vision science & technology · 2020Article
- Comparative Study Between the SORS and Dynamic Strategy Visual Field Testing Methods on Glaucomatous and Healthy Subjects.Translational vision science & technology · 2020Article
- Improvements in Test-Retest Variability of Static Automated Perimetry by Censoring Results With Low Sensitivity in Retinitis Pigmentosa.Translational vision science & technology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeAutomated perimetry does not produce reliable estimates of true psychophysical threshold in glaucomatous visual fields when the perimetric threshold falls below 15 to 19 dB. It may be possible to truncate testing at such locations and not use stimuli with very high contrast. However, this can only be recommended if it does not harm the ability to monitor change. This study examined the effect of applying such a cutoff by censoring sensitivities in two existing longitudinal datasets.
methodsSeries of six visual fields were taken from participants with glaucoma or high-risk ocular hypertension in the Portland Progression Project (P3) and Rotterdam Eye Study (RES). Pointwise linear regression was used to find "progressing" locations, defined as a slope ≤ -1 dB/y with P < 1%. An eye was labeled progressing if ≥3 locations were progressing. This was repeated after setting any sensitivities below the cutoff value C (CdB) to instead equal that value for different integer values of CdB.
resultsIn the P3 cohort tested using Swedish Interactive Testing Algorithm (SITA) Standard, censoring below 15 to 19 dB did not reduce the number of eyes flagged as progressing. For the RES cohort tested using the Full Threshold algorithm, censoring below 10 dB did not reduce the number of eyes flagged as progressing, but a modest reduction was seen for CdB between 10 dB and 15 to 19 dB.
conclusionsThe proportion of eyes flagged as progressing was not decreased by censoring unreliable sensitivities. Restricting the range of contrast used in clinical perimetry may be possible without hampering the ability to monitor glaucomatous visual field progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.